Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Sirtuin modulators control reactive gliosis in an in vitro model of Alzheimer's disease.

Scuderi C, Stecca C, Bronzuoli MR, Rotili D, Valente S, Mai A, Steardo L.

Front Pharmacol. 2014 May 13;5:89. doi: 10.3389/fphar.2014.00089. eCollection 2014.

2.

Modulation of sirtuins: new targets for antiageing.

Pallàs M, Verdaguer E, Tajes M, Gutierrez-Cuesta J, Camins A.

Recent Pat CNS Drug Discov. 2008 Jan;3(1):61-9. Review.

PMID:
18221243
3.

The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations.

Bonda DJ, Lee HG, Camins A, Pallàs M, Casadesus G, Smith MA, Zhu X.

Lancet Neurol. 2011 Mar;10(3):275-9. doi: 10.1016/S1474-4422(11)70013-8. Review.

4.

Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence.

Albani D, Polito L, Forloni G.

J Alzheimers Dis. 2010;19(1):11-26. doi: 10.3233/JAD-2010-1215. Review.

PMID:
20061622
5.

Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease.

Mori T, Koyama N, Arendash GW, Horikoshi-Sakuraba Y, Tan J, Town T.

Glia. 2010 Feb;58(3):300-14. doi: 10.1002/glia.20924.

6.

The difference in gliosis induced by β-amyloid and Tau treatments in astrocyte cultures derived from senescence accelerated and normal mouse strains.

Lü L, Mak YT, Fang M, Yew DT.

Biogerontology. 2009 Dec;10(6):695-710. doi: 10.1007/s10522-009-9217-3.

PMID:
19221889
7.

SIRT1 and SIRT2: emerging targets in neurodegeneration.

Donmez G, Outeiro TF.

EMBO Mol Med. 2013 Mar;5(3):344-52. doi: 10.1002/emmm.201302451. Epub 2013 Feb 18. Review.

8.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
9.

In vitro and in vivo activation of astrocytes by amyloid-beta is potentiated by pro-oxidant agents.

García-Matas S, de Vera N, Aznar AO, Marimon JM, Adell A, Planas AM, Cristòfol R, Sanfeliu C.

J Alzheimers Dis. 2010;20(1):229-45. doi: 10.3233/JAD-2010-1365.

PMID:
20164580
10.

Resveratrol--a boon for treating Alzheimer's disease?

Anekonda TS.

Brain Res Rev. 2006 Sep;52(2):316-26. Review.

PMID:
16766037
11.

Potential of chromatin modifying compounds for the treatment of Alzheimer's disease.

Karagiannis TC, Ververis K.

Pathobiol Aging Age Relat Dis. 2012;2. doi: 10.3402/pba.v2i0.14980. Epub 2012 Feb 20.

12.

[Alzheimer's disease: new prospects in therapy and applied experimental models].

Kubis AM, Janusz M.

Postepy Hig Med Dosw (Online). 2008 Aug 5;62:372-92. Review. Polish.

13.

KCa3.1 constitutes a pharmacological target for astrogliosis associated with Alzheimer's disease.

Yi M, Yu P, Lu Q, Geller HM, Yu Z, Chen H.

Mol Cell Neurosci. 2016 Aug 24;76:21-32. doi: 10.1016/j.mcn.2016.08.008. [Epub ahead of print]

PMID:
27567685
14.

Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer's Disease.

Braidy N, Jugder BE, Poljak A, Jayasena T, Mansour H, Nabavi SM, Sachdev P, Grant R.

Curr Top Med Chem. 2016;16(17):1951-60.

PMID:
26845555
15.

Inhibition of Sirtuin 2 with Sulfobenzoic Acid Derivative AK1 is Non-Toxic and Potentially Neuroprotective in a Mouse Model of Frontotemporal Dementia.

Spires-Jones TL, Fox LM, Rozkalne A, Pitstick R, Carlson GA, Kazantsev AG.

Front Pharmacol. 2012 Mar 12;3:42. doi: 10.3389/fphar.2012.00042. eCollection 2012.

16.

Neuroprotective properties of resveratrol in different neurodegenerative disorders.

Albani D, Polito L, Signorini A, Forloni G.

Biofactors. 2010 Sep-Oct;36(5):370-6. doi: 10.1002/biof.118. Review.

PMID:
20848560
17.

Calcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer's models.

Norris CM, Kadish I, Blalock EM, Chen KC, Thibault V, Porter NM, Landfield PW, Kraner SD.

J Neurosci. 2005 May 4;25(18):4649-58.

18.

SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis.

Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, Puigserver P, Sinclair DA, Tsai LH.

EMBO J. 2007 Jul 11;26(13):3169-79. Epub 2007 Jun 21.

19.

The role of sirtuins in Alzheimer's disease.

Lalla R, Donmez G.

Front Aging Neurosci. 2013 Apr 9;5:16. doi: 10.3389/fnagi.2013.00016. eCollection 2013.

20.

Inflammatory process in Alzheimer's Disease.

Meraz-Ríos MA, Toral-Rios D, Franco-Bocanegra D, Villeda-Hernández J, Campos-Peña V.

Front Integr Neurosci. 2013 Aug 13;7:59. doi: 10.3389/fnint.2013.00059. eCollection 2013.

Items per page

Supplemental Content

Write to the Help Desk